Odyssey Therapeutics, Inc.
ODTX
Positions held
Your positionsODTX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Odyssey Therapeutics operates in the biotechnology sector, which is known for its potential to deliver groundbreaking therapies and treatments, appealing to long-term investors looking for innovation.
- The company's current ratio stands at 11.36, indicating strong liquidity and the ability to cover short-term obligations.
- Odyssey Therapeutics has a target mean price of $35.75, suggesting significant upside potential from its current market price.
- The company has a high debt-to-equity ratio of 5.894, raising concerns about financial stability and risk.
- In the most recent quarter, Odyssey reported an operating margin of -4430.3%, reflecting severe operational inefficiencies.
- The stock has a 'Strong Sell' signal with a score of -16.00, indicating negative market sentiment and a downward trend.
Fundamentals
| Market cap | $870.82M | Enterprise value | $582.53M | Trailing P/E | — | Forward P/E | -4.16 |
| PEG | — | Price / book | 2.06 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | -1563.9% |
| Profit margin | 0.0% | ROE | — | ROA | — | Debt / equity | 0.06 |
| Current ratio | 11.36 | Free cash flow | — | Analyst recommendation | none | Mean target | $35.75 |
| 52w high | $29.05 | 52w low | $15.10 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $1.0M | $1.9M |
| Op margin | — | — | -4430.3% | -2336.2% |
| Net income | -$52.8M | -$38.3M | -$41.2M | -$38.4M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$46.7M | -$39.7M | -$42.5M | -$44.8M |
- Operating margin compressed to -4430.3%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $3.0M | $4.5M | $1.0M | $0.0M |
| Op margin | -5415.2% | -3023.8% | -12867.8% | — |
| Net income | -$149M | -$129M | -$126M | -$125M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$161M | -$135M | -$133M | -$123M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-16 · Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum
2026-09-14 · Odyssey Therapeutics (ODTX) Banks Two More Years As Trials Multiply
2026-08-27 · HC Wainwright Initiates Odyssey Therapeutics at Buy With $44 Price Target
2026-08-26 · Odyssey Therapeutics to Participate in Upcoming Investor Conferences
2026-08-11 · Odyssey Therapeutics (ODTX) Looks Fully Valued As Earnings And Evotec Deal Refocus Attention
2026-08-07 · Evotec and Odyssey collaborate on AI-enabled R&D
2026-08-06 · Odyssey Therapeutics: Q2 Earnings Snapshot
2026-08-06 · Evotec, Odyssey Therapeutics Partner to Develop Autoimmune, Inflammatory Disease Treatments
2026-08-04 · Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Price (daily)
Full chart · RSI · MACD · patterns